Videos

Noa Biran, MD, discusses how selinexor targets nuclear export, inducing apoptosis in multiple myeloma cells. Its synergistic potential with approved agents makes it suitable across refractory cases, bridging therapy options and improving patients' quality of life.

Vinay Raja, MD, explores the crucial role of adjuvant immunotherapy in resectable stage III NSCLC, providing insights into patient selection criteria, considerations for choosing among available treatment options, and the impact of recent trial data updates on informing treatment decisions in this evolving therapeutic landscape.

Oncology experts from the University of Kansas discuss the evolving role of neoadjuvant/perioperative immunotherapy in resectable stage-III NSCLC, analyzing recent trial data and addressing the nuanced factors that inform their decisions between neoadjuvant and perioperative treatments in clinical practice.

Alykhan Nagji, MD, provides an overview of the institutional approach to determining eligibility for surgical resection, delving into the pivotal role of the multidisciplinary tumor board in the decision-making process and exploring the crucial factors that must be considered when evaluating resectability.

A summary of key discussion points and an overview of the evidence presented to inform the dialogue.

Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.

Sagar Lonial, MD, and Ellen Marin, PA-C, discuss the impact and key takeaways from their study as well as study limitations and future directions.

Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to share their closing thoughts before the 2-Minute Drill winner is announced.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to provide shameless plugs from this year's conference.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss the biggest winner from the 2023 meeting.

Three medical oncologists explore the influence of MRD negativity rates on treatment decisions and discover the ideal patient profile for quadruplet regimen.

Larry Anderson, MD, goes over the recent data from the IsKia trial which investigated IsaKRd in pre-transplant induction and post-transplant consolidation in TE NDMM.

Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.

Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.

Expert faculty discuss consideration factors in guiding frontline treatment selection with BTKis in CLL.

A panel of oncology experts explore recent updates from SEQUOIA and ELEVATE-RR, discussing the potential impact of these findings on the clinical practice setting.

A panel of oncology experts discuss the role of 1L combination therapy using obinutuzumab plus a BTKi, highlighting key consideration factors for patient selection.

Noa Biran, MD, discusses how the phase III BOSTON trial evaluates selinexor + bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed/refractory myeloma.

Noa Biran, MD, reviews approved bispecific T-cell engagers and how they redefine multiple myeloma treatment, yielding high response rates in refractory cases, but their use necessitates careful evaluation in later therapy lines.

Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.

Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.

Study results show that prophylactic tocilizumab reduces CRS incidence and severity in patients receiving teclistamab.

Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.

Fatigue and mouth sores are some of the common adverse effects associated with treatment using palbociclib or ribociclib, says Sarah Donahue, MPH, NP.

Treatment with CDK4/6 inhibitors does not appear to result in severe neutropenic fever compared with chemotherapy for breast cancer, according to Sarah Donahue, MPH, NP.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that require the most follow-up.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that are most likely to lead to an FDA approval.

Susan Dent, MD, delves into the exploration of front-line treatment options for triple-positive breast cancer and examines strategies for restaging in the event of disease progression after first-line therapy.

Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.